Management
Epigenomics is managed by a team characterized by a unique mix of seasoned diagnostics industry experience, science and management expertise, and the entrepreneurial commitment to build a world-leading cancer molecular diagnostics company.
Dr. Thomas Taapken, CEO/CFO
Dr. Thomas Taapken is CEO of Epigenomics AG since September 2012. He joined Epigenomics on April 1, 2011 as Chief Financial Officer. from Biotie Therapies (Finland), where he held the position of CFO and was a member of the Executive Management Team. He was appointed to this position in 2008, following a business combination between Biotie Therapies and elbion NV, where Thomas had been CFO since 2005. His extensive international experience in the life sciences industry includes previous positions as investment partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Francisco-based US venture capital firm Burrill & Company from 1998-2002. He also worked several years at Sanofi-Aventis in the U.S.A. and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings.
Dr. Uwe Staub, Chief Operating Officer
Uwe Staub, COO of the Company, has been appointed to the Executive Board, effective April 1, 2013. He studied Biology at the University of Wuerzburg, Germany, and earned his PhD in Biochemistry and Human Genetics. Before joining Epigenomics, Uwe worked 14 years in the IVD industry for Abbott Diagnostics, Digene and Qiagen and gained experience in Operations, Quality and Regulatory Affairs as well as Product Development. Uwe heads Epigenomics' R&D, Clinical Research and Regulatory, Customer Support and Manufacturing Department.
Noel Doheny, CEO Epigenomics Inc.
Noel joined Epigenomics in May 2011 to head our U.S. commercial operations as CEO of our U.S. Subsidiary Epigenomics Inc. Noel brings in 30+ years of experience in the field of diagnostics, with over 20 years in senior management. Prior to joining Epigenomics, he held positions as CEO of OpGen, Senior Vice President for the Molecular Diagnostics Division of Affymetrix Inc., Vice President of Pre-Analytical Solutions and a member of the Executive Committee at QIAGEN as well as President and CEO of BioStar Inc. He has built several operating teams from the ground up, including the commercial teams to launch novel products at companies such as Ciba Corning, Biostar, and OpGen. Noel obtained degrees in Biology and Chemistry from West Virginia University and attended Georgetown University for post-graduate studies in Biochemistry prior to moving into industry.
Albert Weber, Senior Vice President Finance, Accounting & Controlling
Albert earned his degree in business administration at the University of Cologne. After several years in various accounting and treasury functions with international corporate players (Sony, EMI), he joined a German IT start-up and accompanied this company through a successful IPO. In 2000, he joined Epigenomics. He heads the entire accounting, controlling and treasury as well as the IT systems administration, the purchasing and the general administration. As project manager in charge he guided Epigenomics through several successful financing transactions. Albert is a proxy holder for the company.